Use of Aripiprazole in treatment resistant schizophrenia

Journal of Psychopharmacology

Volumn 22, Issue 8, 2008, Pages 927-928

  Hughes, D ^a,b   Morcos, M ^a,b  

^a GREATER MANCHESTER MENTAL HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^b Meadowbrook Psychiatric Unit   (United Kingdom)

Author keywords

Aripiprazole; Clozapine; Treatment resistant schizophrenia

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; CLONAZEPAM; CLOZAPINE; DOMPERIDONE; FLUPENTIXOL DECANOATE; OLANZAPINE; QUETIAPINE; SULPIRIDE; VALPROIC ACID; ZUCLOPENTHIXOL DECANOATE;

ADD ON THERAPY; ADULT; ARTICLE; CASE REPORT; CREATINE KINASE BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPOTENSION; INTERNATIONAL CLASSIFICATION OF DISEASES; MALE; NEUTROPENIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DRUG RESISTANCE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; QUINOLONES; SCHIZOPHRENIA;

EID: 54249089305     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881107083850     Document Type: Article

References (2)

1. Burstein ES, Ma J., Wong S., Gao Y., Pham AE, Knapp AE, Nash NR, Olsson R., Davis RE, Hacksell U., Weiner DM, and Brann MR (2005) Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. J Pharmacol Experiment Ther JPET 315: 1278-1287
2. Weiner DM, Meltzer HY, Veinbergs I., Donohue EM, Spalding TA, Smith TT, Mohell N., Harvey SC, Lameh J., Nash N., Vanover KE, Olsson R., Jayathilake K., Lee M., Levey AI, Hacksell U., Burstein ES, Davis RE, Brann MR (2004) The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of Clozapine. Psychopharmacology 177: 207-216 [Medline]